Chronic Kidney Disease – Landscape & Forecast – Disease Landscape & Forecast
Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive agents and SGLT-2 inhibitors, which are intended to delay the progression of kidney damage. RAAS inhibitors are the standard of care for CKD. In 2021, AstraZeneca’s Farxiga (dapagliflozin) became the first SGLT-2 inhibitor to demonstrate a renoprotective effect in a dedicated CKD outcomes trial and to receive formal approval from the FDA for the treatment of CKD irrespective of the presence or absence of diabetes. In 2022, Eli Lilly’s Jardiance (empagliflozin) demonstrated renoprotective benefits among CKD patients in the EMPA-KIDNEY trial; this SGLT-2 inhibitor is expected to receive a label expansion to CKD in 2023. Johnson & Johnson’s Invokana (canagliflozin) also demonstrated renoprotective benefits in diabetic patients with CKD in the CREDENCE trial. Thus, SGLT-2 inhibitors are set to play an increasingly important role in CKD treatment. In 2021, Bayer’s Kerendia (finerenone), a mineralocorticoid receptor antagonist, was approved for CKD after demonstrating renoprotective and cardioprotective benefits in type 2 diabetes patients with CKD in the FIDELIO-DKD and FIGARO-DKD trials. Supported by insights from thought leaders, we analyze the challenges associated with marketing drugs to treat an increasingly dynamic and complex disease.
Questions answered
- Does the inclusion of cardiovascular endpoints in clinical trials of select CKD therapies confer a competitive advantage once the therapies become commercially available?
- Are SGLT-2 inhibitors set to become the standard-of-care therapy for CKD?
- How do KOLs view the advantages and disadvantages of current therapies and the mechanisms of action of emerging therapies?
- What are the greatest unmet needs in CKD? Which drugs in development will fulfill these unmet needs?
- What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Chronic Kidney Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Chronic Kidney Disease Key Findings - August 2023
- Key Updates
- August 2023
- February 2023
- January 2023
- Q4 2022
- October 2022
- Q3 2022
- September 2022
- Market Outlook
- Key findings
- Market share of drug classes for chronic kidney disease: 2022
- Market share of drug classes for chronic kidney disease: 2032
- Chronic kidney disease SWOT analysis
- Market drivers and constraints
- What factors are driving the market for chronic kidney disease?
- What factors are constraining the market for chronic kidney disease?
- Annual sales for total chronic kidney disease by chronic kidney disease stage: 2022-2032
- Annual sales of drug classes for total chronic kidney disease: 2022-2032
- Annual patient share of key drug classes for stage 2 chronic kidney disease: 2022-2032
- Annual patient share of key drug classes for stage 3 chronic kidney disease: 2022-2032
- Annual patient share of key drug classes for stage 4 chronic kidney disease: 2022-2032
- Annual patient share of key drug classes for stage 5 chronic kidney disease: 2022-2032
- Drug-class-specific trends
- Annual sales of SGLT-2 inhibitors in chronic kidney disease in major markets: 2022-2032
- Annual patient share of SGLT-2 inhibitors in chronic kidney disease in the United States: 2022-2032
- Annual sales of SGLT-2 inhibitors in chronic kidney disease in the United States: 2022-2032
- Annual patient share of SGLT-2 inhibitors in chronic kidney disease in Europe: 2022-2032
- Annual sales of SGLT-2 inhibitors in chronic kidney disease in Europe: 2022-2032
- Annual patient share of SGLT-2 inhibitors in chronic kidney disease in Japan: 2022-2032
- Annual sales of SGLT-2 inhibitors in chronic kidney disease in Japan: 2022-2032
- Annual sales of mineralocorticoid receptor antagonists in chronic kidney disease in the United States: 2022-2032
- Annual sales of mineralocorticoid receptor antagonists in chronic kidney disease in Europe: 2022-2032
- Annual sales of mineralocorticoid receptor antagonists in chronic kidney disease in Japan: 2022-2032
- Annual patient share of mineralocorticoid receptor antagonists in chronic kidney disease in the United States: 2022-2032
- Annual patient share of mineralocorticoid receptor antagonists in chronic kidney disease in Europe: 2022-2032
- Annual patient share of mineralocorticoid receptor antagonists in chronic kidney disease in Japan: 2022-2032
- Semaglutide
- Major-Market patient share of semaglutide in chronic kidney disease: 2022 - 2032
- Major-Market annual sales of semaglutide in chronic kidney disease: 2022 - 2032
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Etiology
- Risk factors for chronic kidney disease
- Pathophysiology
- Classification of chronic kidney disease by estimated glomerular filtration rate
- Classification of chronic kidney disease by proteinuria
- Key pathways and drug targets
- Drug targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods and sources used
- Prevalent cases of chronic kidney disease: 2022-2032
- Diagnosed prevalent cases of chronic kidney disease: 2022-2032
- Drug-treated prevalent cases of chronic kidney disease: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for chronic kidney disease
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for chronic kidney disease
- Current treatments used for chronic kidney disease
- Market events impacting the use of key current therapies for chronic kidney disease
- Dapagliflozin
- Advantages and disadvantages of dapagliflozin
- Key results from select clinical trials investigating dapagliflozin for the treatment of chronic kidney disease
- Expert insight: dapagliflozin
- Empagliflozin
- Advantages and disadvantages of empagliflozin
- Key results from select clinical trials investigating empagliflozin for the treatment of chronic kidney disease
- Expert insight: empagliflozin
- Canagliflozin
- Advantages and disadvantages of canagliflozin
- Key results from select clinical trials investigating canagliflozin for the treatment of chronic kidney disease
- Expert insight: canagliflozin
- Advantages and disadvantages of RAAS inhibitors
- Expert insight: RAAS inhibitors
- Other antihypertensive drug classes
- Expert insight: other antihypertensives
- Medical practice
- Overview
- Factors influencing drug selection in chronic kidney disease
- Treatment decision tree for chronic kidney disease: United States
- Treatment decision tree for chronic kidney disease: Europe
- Treatment decision tree for chronic kidney disease: Japan
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in chronic kidney disease
- Top unmet needs in chronic kidney disease: current and future attainment
- Expert insight: unmet need in chronic kidney disease
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for chronic kidney disease
- Estimated launch dates of key emerging therapies for the treatment of chronic kidney disease
- Key results from select clinical trials investigating finerenone for the treatment of chronic kidney disease
- Key ongoing clinical trials of finerenone in the treatment of chronic kidney disease
- Analysis of the clinical development program for finerenone
- Expert insight: finerenone
- Expectations for launch and sales opportunity of finerenone in chronic kidney disease
- Key results from select clinical trials investigating semaglutide for the treatment of chronic kidney disease
- Key ongoing clinical trials of semaglutide in the treatment of chronic kidney disease
- Analysis of the clinical development program for semaglutide
- Expert insight: semaglutide
- Expectations for launch and sales opportunity of semaglutide in chronic kidney disease
- Renal autologous cell therapies profile
- Key ongoing clinical trials of renal autologous cell therapies in the treatment of chronic kidney disease
- Analysis of the clinical development program for renal autologous cell therapies
- Expert insight: REACT
- Expectations for launch and sales opportunity of renal autologous cell therapy in chronic kidney disease
- Early-phase pipeline analysis
- Select compounds in early-phase development for chronic kidney disease
- Key discontinuations and failures in chronic kidney disease
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in chronic kidney disease: United States
- General reimbursement environment: United States
- Key market access considerations in chronic kidney disease: EU5
- General reimbursement environment: EU5
- Key market access considerations in chronic kidney disease: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Chronic kidney disease bibliography
- Key Findings
Dwaipayan Chatterjee, M.Pharm., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders analyst. Mr. Chatterjee authors reports on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.